The clinical information you need, at your fingertips.

Plasma pTau217 predicts early brain pathology and cognitive decline in cognitively normal older adults. . .

West Health–Gallup survey finds one in four adults using AI tools to supplement—and sometimes replace—clinical care. . .

In the approval letter, the agency outlined additional post‑approval clinical trials to further characterize safety. . .

Study findings suggest that emotional well-being may influence who develops degenerative valve disease over time. . .

Large European registry shows standard-dose bismuth quadruple therapies perform just as well as intensified regimens. . .

Filspari (sparsentan) is the first FDA-approved drug for FSGS, a rare kidney disease historically treated with off-label options and supportive care. . .

Large cluster randomized trial shows patient education plus clinician guidance doubles deprescribing rates without worsening reflux symptoms. . .

Once-daily oral daraxonrasib significantly improves overall survival and progression-free survival vs. chemotherapy in previously treated patients. . .

Among patients eligible for short‑course therapy (~10%), outcomes were similar with 3 to 4 vs. 5 or more days of antibiotics. . .